Non-alcoholic fatty liver disease: new therapeutic options

R. G. Myazin
2014 Medical Council  
The past decades have recorded sustainably high incidence of non-alcoholic fatty liver disease (NAFLD) globally. The disease is more prevalent among people with obesity and diabetes mellitus (DM), dyslipidemia and metabolic syndrome (MS) [3, 4]. NAFLD is an independent nosological unit including a range of clinical and morphological changes of the liver parenchyma: steatosis (fatty degeneration) and non-alcoholic steatohepatitis. NAFLD pharmacotherapy asks for a search of new effective methods
more » ... effective methods of treatment.
doi:10.21518/2079-701X-2014-13-18-21 doaj:0833a07d0eec49aaa4c5d7140925a764 fatcat:uon6etixnzgy5ltarpozk6qkti